PsychedelicNewsBreaks

FridayJan 13, 2023 12:00 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of up to 1,925,210 of HUGE subordinate class B voting shares over the next 12 months at prevailing market prices. The program will enable the company to use excess cash reserves in strategic ways designed to return value to shareholders. “FSD Pharma is focused on the advancement of…

Continue Reading

ThursdayJan 12, 2023 10:34 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent,” said Cybin CEO Doug Drysdale. “Since the pandemic, the prevalence of depression and…

Continue Reading

MondayJan 09, 2023 11:55 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

Continue Reading

MondayJan 09, 2023 10:27 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

Continue Reading

FridayJan 06, 2023 11:35 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi…

Continue Reading

WednesdayJan 04, 2023 1:48 pm

PsychedelicNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Recaps 2022, Eyes 2023 as ‘Pivotal Year’

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered care, today provided a year-end summary of 2022 accomplishments. “2022 was a busy year of behind-the-scenes activity laying the foundations with Health Canada in preparation for the planned clinical trial application and sourcing the related ibogaine drug supply,” said Nick Karos, chief executive officer and board member of Universal Ibogaine. “We are finalizing discussions with several potential funding partners and intend on closing the second round of our current convertible debt financing very shortly. 2023 will be a pivotal…

Continue Reading

TuesdayDec 20, 2022 11:13 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady progress across our pipeline of differentiated psychedelic-based therapeutics and partnerships targeting mental health. Most notable were the advancements of our two lead programs, CYB003 and CYB004, into clinical stage – within less than 18 months since discovery – which is a remarkable accomplishment and a true testament to the strength of our team,” said Cybin’s Chief Executive Officer Doug Drysdale. “Along with our clinical programs,…

Continue Reading

WednesdayDec 07, 2022 11:06 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder (“MDD”). “These new findings demonstrate the unique PK properties of CYB003 compared with classical psilocybin and further supports our ongoing first-in-human phase 1/2a clinical trial evaluating CYB003 for the treatment…

Continue Reading

WednesdayNov 30, 2022 10:59 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the board of directors. Dr. Kotra, an academic entrepreneur, has contributed to a number of important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He is the recipient of…

Continue Reading

MondayNov 21, 2022 12:24 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue, with initial data expected during the first quarter of 2023. “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where…

Continue Reading